Marina Biotech is a leading clinical-stage RNA therapeutics company focused on research and development of novel therapeutics for significant unmet medical needs based on the Nobel Prize winning discovery of RNA interference. We will continue to develop and acquire multiple drug discovery and delivery technologies necessary to broadly capitalize on the advantages of an RNAi-based therapeutic across a variety of human disease. Learn More
 | Webcast 09/13/10 at 3:15 p.m. ET Marina Biotech, Inc. at Rodman & Renshaw Global Investment Conference – 12th Annual Healthcare Conference (Live) |
Featured Reports
|
|
Stock Quote |
Featured News
- 08/30/10Marina Biotech Announces Allowance of Fundamental RNAi Delivery Patent From U.S. Patent Office
- 08/26/10Marina Biotech Sells Carbetocin Asset to Cypress Bioscience
- 08/24/10Marina Biotech Announces Issuance of a U.S. Patent Broadly Covering Its Amphoteric Liposomal siRNA Delivery Technology
- 08/12/10Marina Biotech, Inc. Announces Second Quarter 2010 Financial Results
Contact Information
| Primary IR Contact |
| John Woolford Westwicke Partners Phone: 443-213-0506 E-mail: ir@marinabio.com |
| Transfer Agent |
| American Stock Transfer & Trust Company 59 Maiden Lane New York, NY 10038 Phone: 877-777-0800 Corporate Website: http://www.amstock.com |
| Legal |
| Pryor Cashman Sherman & Flynn LLP 410 Park Avenue New York, NY 10022 Phone: (212) 421-4100 Corporate Website: http://www.pryorcashman.com |
| Accountants |
| KPMG 3100 Two Union Square 801 Second Avenue Seattle, WA 98104 Phone: 206-292-1500 Corporate Website: http://www.kpmgcampus.com |
 |
 Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |